Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 894999 in advanced malignancies
NCT02516553Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2015
- Primary completion
- Nov 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of BI 894999 in solid tumor, diffuse large B-cell lymphoma (DLBCL), NUT carcinoma (NC) and 3 more (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With Dose Limiting Toxicities Observed in the First Cycle at 28 days and Number of Patients With Dose Limiting Toxicities Observed During the On-treatment Period at 883 days. Started Jul 2015; status: completed.
02
Drugs
BI 894999
03
Conditions
solid tumordiffuse large B-cell lymphoma (DLBCL)NUT carcinoma (NC)small cell lung cancer (SCLC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02516553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516553.